Lung Cancer

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

Researchers have ruled out race as a prognostic factor for overall survival (OS) in black patients with a lung cancer diagnosis.

It was not so long ago that designing an optimal treatment plan for an individual cancer patient required only a confirmed histologic/morphologic diagnosis of a particular tumor type and appropriate staging, which was surgically based in most solid tumors.

There's been a flurry of activity in recent weeks when it comes to oncology drug filings at the FDA. While every application is unique, the agency is required to decide within 60 days whether a new drug application (NDA) will move forward for a full review.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States.

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

Non-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.

Men who undergo lung cancer screening are more likely to stop smoking if the results are inconclusive than if they are negative, according to a team of researchers from Denmark.

Star Scientific, a Virginia-based company, has petitioned the FDA to approve the sale of what it claims is a

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.

This year in the US, the American Cancer Society estimates that lung cancer will kill more people than breast, prostate, colon, liver, and kidney cancers combined, making it the leading cause of cancer death among Americans.

The results of Amgen's %u201C145 study%u201D of Aranesp in patient's with late-stage small-cell lung cancer (SCLC) are released.

Chemotherapy is widely used in the treatment of malignant mesothelioma, but it has never been compared in a randomized trial with active symptom control (ASC) alone.

Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the US. At the12th World Conference on Lung Cancer (WCLC), the world%u2019s top lung cancer specialists convened to present and discuss the latest research in this disease. Key themes included accurate targets, new combinations of drugs to reduce toxicity, and strategies to improve outcomes.

Oncology & Biotech News provides updates from major oncology meetings because symposia remain an important means for disseminating new data. This issue, we highlight two important meetings: 2007 Breast Cancer Symposium (in San Francisco) and the World Conference on Lung Cancer (in Korea).

A common treatment option for prostate cancer is radiation therapy, which is as effective in treating the disease as surgical removal of the prostate.

Highlights from the 50th Annual Meeting of the American Society of Hematology.

A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis’ novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC).

Lately, ultrasound has been used to increase sampling accuracy. Trans-thoracic ultrasound does not provide adequate guidance because of the difficulty in imaging the mediastinum